Held on 24-25 March 2025 in Brussels, the first Global Lp(a) Summit marked a historic inflection point in the global cardiovascular prevention agenda. Convened by the Lp(a) International Taskforce and organised by FH Europe Foundation, the Summit elevated lipoprotein(a) from a largely under-recognised inherited risk factor to a central priority within cardiovascular health policy discourse.
Hosted under the patronage of the Polish Presidency of the Council of the European Union and supported by cross-party Members of the European Parliament, the Summit bridged high-level political leadership with world-class scientific expertise. Persons with lived experience of high Lp(a) concentrations, as well as members from the European Atherosclerosis Society (EAS), International Atherosclerosis Society (IAS), World Heart Federation (WHF), and World Health Organization (WHO) were further cornerstones of this meeting, which brought people from five continents together.
The Summit convened leading lipidologists, cardiologists, geneticists, epidemiologists, health economists, European Union policymakers, World Health Organisation representatives, patient advocates, and digital health experts.
This cross-sectoral composition ensured that discussions moved beyond scientific validation to address reimbursement frameworks, digital infrastructure, workforce training, ethical governance, and real-world implementation.
Updated epidemiological and mechanistic evidence reaffirmed elevated Lp(a) as an independent and causal risk factor for ASCVD, aortic stenosis, stroke, and premature cardiovascular mortality.
New international cost-effectiveness modelling presented compelling evidence that once-in-a-lifetime Lp(a) testing, when integrated into prevention pathways, represents a fiscally responsible intervention aligned with long-term health system sustainability.
Experts examined how electronic health records, risk calculators, AI-supported stratification, and population registries can enable systematic and equitable integration of Lp(a) measurement.
Sessions addressed informed consent, cascade testing, testing in children, health inequalities, and psychosocial impact, ensuring that implementation frameworks remain ethically robust and socially responsive.
The Summit culminated in the formal launch of the Brussels International Declaration on Lp(a) Testing and Management, a landmark policy document translating scientific consensus into a structured, actionable political roadmap. The Global Lp(a) Summit established an enduring platform for annual scientific-policy dialogue and positioned the Lp(a) International Taskforce as the coordinating global body for strategic implementation.